IV Haloperidol for the Treatment of Headache in the ED
This trial is active, not recruiting.
|Conditions||headache, migraine disorders|
|Sponsor||Western Michigan University School of Medicine|
|Start date||October 2015|
|End date||July 2017|
|Trial size||159 participants|
|Trial identifier||NCT02747511, BMH-2015-0811|
Single center, double-blind, randomized, placebo-controlled trial evaluating analog pain scores in patients who present to the emergency department (ED) with a complaint of headache. A total of 150 patients age 13-55 presenting to the emergency department with headache will be enrolled from October 2015 - October 2016. Patients will be randomized and pain scores and side effects will be recorded at 0, 30, 60, and 90 minutes. Follow-up will be performed by telephone at 24 hours.
|Intervention model||parallel assignment|
>50% reduction in pain per Visual Analog Scale (VAS)
time frame: 90 minute interval
All participants from 13 years up to 55 years old.
Inclusion Criteria: - Emergency Department patients that complain of headache or migraine - Males and females age 13-55 - English is primary language Exclusion Criteria: - Abnormal blood pressure (>200/100) - Sudden rapid onsent (normal to worst pain in minutes) - Fever - Trauma - Any history of masses, strokes, head injury or other causes of abnormal anatomy - QT greater than 450 ms on EKG - Allergy to Haldon - Any altered mental status (GCS <15) - Pregnancy - Any abnormalities on neurologic exam - Any clinician concern that would require CT scan of brain - Any prisoner or ward of state
|Official title||Intravenous Haloperidol for the Treatment of Headache in the Emergency Department|
Call for more information